Single-cell analysis of peripheral CD8⁺ T cell responses in patients receiving checkpoint blockade immunotherapy for cancer.

ABSTRACT: Checkpoint blockade immunotherapy has become a first-line treatment option for cancer patients, with success in increasingly diverse cancer types. Still, many patients do not experience durable responses and the reasons for clinical success versus failure remain largely undefined. Investigation of immune responses within the tumor microenvironment can be highly informative but access to tumor tissue is not always available, highlighting the need to identify biomarkers in the blood that correlate with clinical success. Here, we used single-cell RNA sequencing coupled with T cell receptor sequencing to define CD8⁺ T cell responses in peripheral blood of two patients with melanoma before and after immunotherapy with either anti-PD-1 (nivolumab) alone or the combination of anti-PD-1

SUBMITTER: Khojandi N 

PROVIDER: S-EPMC10306114 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature